Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hugo Geerts

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
Alzheimer'S & Dementia (New York, N. Y.)|May 22, 2024
Quantitative systems pharmacology-based exploration of relevant anti-amyloid therapy challenges in clinical practiceHugo Geerts, Silke Bergeler, Mike Walker, et al.
Journal of Pharmacokinetics and Pharmacodynamics|October 9, 2022
A quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson's disease: application to preladenantRachel Rose, Emma Mitchell, Piet Van Der Graaf, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 29, 2025
Interactions of Therapeutic Antibodies With Presynaptically-Released Misfolded Proteins in Neurodegenerative Diseases. A Spatial Monte-Carlo Simulation StudyJamie Goff, Maryam Khalifa, Shaina M Short, et al.
Scientific Reports|September 1, 2023
Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology modelHugo Geerts, Silke Bergeler, Mike Walker, et al.
Journal of Psychopharmacology (Oxford, England)|September 21, 2018
Predicting parkinsonism side-effects of antipsychotic polypharmacy prescribed in secondary mental healthcareGiouliana Kadra, Athan Spiros, Hitesh Shetty, et al.
Proteomics|July 12, 2002
Proteomics analysis of the neurodegeneration in the brain of tau transgenic miceKelly Tilleman, Chris Van den Haute, Hugo Geerts, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 15, 2021
Quantitative systems pharmacology in neuroscience: Novel methodologies and technologiesPeter Bloomingdale, Tatiana Karelina, Murat Cirit, et al.
Journal of Alzheimer'S Disease : JAD|June 4, 2019
Lithium as a Treatment for Alzheimer's Disease: The Systems Pharmacology PerspectiveHarald Hampel, Simone Lista, Dalila Mango, et al.
Alzheimer Disease and Associated Disorders|December 6, 2005
Neuroprotection and neurodegenerative diseases: from biology to clinical practiceYvette Akwa, Hervé Allain, Danièle Bentue-Ferrer, et al.
Methods in Molecular Biology (Clifton, N.J.)|October 3, 2002
Neuropathobiology in transgenic mice. The case of Alzheimer's diseaseJo Van Dorpe, Kurt Spittaels, Chris Van Van den Haute, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Alzheimer'S & Dementia (New York, N. Y.)|May 22, 2024
Quantitative systems pharmacology-based exploration of relevant anti-amyloid therapy challenges in clinical practiceHugo Geerts, Silke Bergeler, Mike Walker, et al.
Journal of Pharmacokinetics and Pharmacodynamics|October 9, 2022
A quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson's disease: application to preladenantRachel Rose, Emma Mitchell, Piet Van Der Graaf, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 29, 2025
Interactions of Therapeutic Antibodies With Presynaptically-Released Misfolded Proteins in Neurodegenerative Diseases. A Spatial Monte-Carlo Simulation StudyJamie Goff, Maryam Khalifa, Shaina M Short, et al.
Scientific Reports|September 1, 2023
Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology modelHugo Geerts, Silke Bergeler, Mike Walker, et al.
Journal of Psychopharmacology (Oxford, England)|September 21, 2018
Predicting parkinsonism side-effects of antipsychotic polypharmacy prescribed in secondary mental healthcareGiouliana Kadra, Athan Spiros, Hitesh Shetty, et al.
Proteomics|July 12, 2002
Proteomics analysis of the neurodegeneration in the brain of tau transgenic miceKelly Tilleman, Chris Van den Haute, Hugo Geerts, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 15, 2021
Quantitative systems pharmacology in neuroscience: Novel methodologies and technologiesPeter Bloomingdale, Tatiana Karelina, Murat Cirit, et al.
Journal of Alzheimer'S Disease : JAD|June 4, 2019
Lithium as a Treatment for Alzheimer's Disease: The Systems Pharmacology PerspectiveHarald Hampel, Simone Lista, Dalila Mango, et al.
Alzheimer Disease and Associated Disorders|December 6, 2005
Neuroprotection and neurodegenerative diseases: from biology to clinical practiceYvette Akwa, Hervé Allain, Danièle Bentue-Ferrer, et al.
Methods in Molecular Biology (Clifton, N.J.)|October 3, 2002
Neuropathobiology in transgenic mice. The case of Alzheimer's diseaseJo Van Dorpe, Kurt Spittaels, Chris Van Van den Haute, et al.
Pageof 8